Venture Investments
Pfizer Venture Investments (PVI), the venture capital arm of Pfizer, Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of the Worldwide Business Development, and Innovation division, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline and shape the future of our industry.
With a $50M annual budget for private investments, PVI may invest up to $10M per round in selected companies in any stage of development, with a strong focus on growth stage opportunities. Other investments, including fund investing, spinout opportunities, and PIPEs will also be considered as appropriate. We actively manage our current portfolio and are seeking to make new investments.
Investment Strategy
We consider investments in a broad array of healthcare related areas, including therapeutics, platform technologies, diagnostics, drug delivery, pharmaceutical services, healthcare IT, and other technologies impacting drug discovery and development. We will consider companies at all stages of development, including start-ups, spinouts, and consortia investments. While primarily U.S. focused, international investments may represent up to 20% of the portfolio. We have the ability to lead or join a syndicate of investors and will seek board representation as appropriate.
Key Points
Active investor — work with management to build shareholder value, assist in product strategy development, and facilitate business development relationships with Pfizer
Ability to utilize the broad network and specialized expertise of Pfizer and its many divisions, contacts, and data sources to benefit portfolio companies
Simple, streamlined approval process for most investment decisions
Potential for Pfizer partnership opportunity and access to large Pharma perspective and pedigree are added to portfolio company's assets
Our Team Is Looking Forward to Working With You
Bill Burkoth
Bill Burkoth, Senior Director
Barbara Dalton
Barbara Dalton, PhD, Vice President
Elaine Jones
Elaine Jones, PhD, Executive Director
Take a look at our investments
Submit your business plan
See Contact List for Venture Investments
We do know that resonance health is working closely with Pfizer on a solution for a liver fibrosis scan.
- Forums
- ASX - By Stock
- RHT
- pfizer 50m annual budget private investment
pfizer 50m annual budget private investment
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RHT (ASX) to my watchlist
|
|||||
Last
5.9¢ |
Change
-0.003(4.84%) |
Mkt cap ! $26.36M |
Open | High | Low | Value | Volume |
6.0¢ | 6.0¢ | 5.9¢ | $30.00K | 501.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 22024 | 5.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.0¢ | 147502 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 22024 | 0.059 |
2 | 1100000 | 0.058 |
1 | 125000 | 0.056 |
1 | 200000 | 0.054 |
1 | 80000 | 0.052 |
Price($) | Vol. | No. |
---|---|---|
0.060 | 9800 | 1 |
0.063 | 20000 | 1 |
0.065 | 122500 | 2 |
0.068 | 100000 | 1 |
0.070 | 150189 | 2 |
Last trade - 15.59pm 28/06/2024 (20 minute delay) ? |
Featured News
RHT (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online